Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

Generation of a CD8(+) response to extracellular antigen requires processing of the antigen by antigen presenting cells (APC) and cross-presentation to CD8(+) T cell receptors via MHC class I molecules. Cross-presentation is facilitated by efficient antigen uptake followed by immune-complex-mediated maturation of the APCs. We hypothesize that improved antigen uptake of a glycopeptide sequence containing a CD8(+) T cell epitope could be achieved by delivering it on a liposome surface decorated with an immune complex-targeting ligand, an l-Rhamnose (Rha) epitope. We synthesized a 20-amino-acid glycopeptide TSAPDT(GalNAc)RPAPGSTAPPAHGV from the variable number tandem repeat region of the tumor marker MUC1 containing an N-terminal azido moiety and a tumor-associated α-N-acetyl galactosamine (GalNAc) at the immunogenic DTR motif. The MUC1 antigen was attached to Pam3Cys, a Toll-like receptor-2 ligand via copper(I)-catalyzed azido-alkyne cycloaddition (CuAAc) chemistry. The Rha-decorated liposomal Pam3Cys-MUC1-Tn 4 vaccine was evaluated in groups of C57BL/6 mice. Some groups were previously immunized to generate anti-Rha antibodies. Anti-Rha antibody expressing mice that received the Rha liposomal vaccine showed higher cellular immunogenicity compared to the control group while maintaining a strong humoral response.

[1]  R. Cummings,et al.  A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Shixia Wang,et al.  Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. , 2006, Journal of virology.

[3]  L. Brown,et al.  Free radical induced polymerization of synthetic peptides into polymeric immunogens. , 1997, Vaccine.

[4]  K. Wiesmüller,et al.  Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. , 1989, Vaccine.

[5]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.

[6]  J. Gariépy,et al.  Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice , 2009, Biological chemistry.

[7]  V. Apostolopoulos,et al.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Hanisch,et al.  Design of a MUC1-based cancer vaccine. , 2005, Biochemical Society transactions.

[9]  K. Rock,et al.  Antigen processing and presentation by the class I major histocompatibility complex. , 1996, Annual review of immunology.

[10]  K. A. Wall,et al.  Synthesis of α-L-rhamnosyl ceramide and evaluation of its binding with anti-rhamnose antibodies. , 2014, Bioorganic & medicinal chemistry.

[11]  W. Bessler,et al.  Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization. , 1997, Behring Institute Mitteilungen.

[12]  L. Kanz,et al.  The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. , 2001, Cancer research.

[13]  U. Galili.  Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody , 2004, Springer Seminars in Immunopathology.

[14]  S. Shohet,et al.  Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues , 1985, The Journal of experimental medicine.

[15]  C. Alving,et al.  Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. , 1994, AIDS Research and Human Retroviruses.

[16]  U. Galili,et al.  Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting Cells , 2007, Journal of Virology.

[17]  K. A. Wall,et al.  Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes. , 2013, Bioconjugate chemistry.

[18]  A. Aderem,et al.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Yan‐Mei Li,et al.  Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells. , 2014, Angewandte Chemie.

[20]  Sven Frokjaer,et al.  Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. , 2004, Vaccine.

[21]  V. Apostolopoulos,et al.  Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. , 2013, Immunotherapy.

[22]  P. Matzinger.  The JAM test. A simple assay for DNA fragmentation and cell death. , 1991, Journal of immunological methods.

[23]  F. Hanisch,et al.  Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. , 2009, Molecular immunology.

[24]  L. Otvos,et al.  Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells , 2002, The Journal of experimental medicine.

[25]  L. Kiessling,et al.  Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti‐Carbohydrate Antibodies to Tumor Cells , 2014, Chembiochem : a European journal of chemical biology.

[26]  L. McShane,et al.  Profiling human serum antibodies with a carbohydrate antigen microarray. , 2009, Journal of proteome research.

[27]  Wenchuan Wu,et al.  Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine , 2009, BMC Cancer.

[28]  P. Bruhns.  Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[29]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000 .

[30]  F. Hanisch,et al.  O-Glycosylated Human MUC1 Repeats Are Processed In Vitro by Immunoproteasomes1 , 2007, The Journal of Immunology.

[31]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[32]  M. E. Tay,et al.  Isomeric, anti-rhamnose antibodies having specificity for rhamnose-containing, streptococcal heteroglycans. , 1983, Carbohydrate research.

[33]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Kurts,et al.  Cross-priming in health and disease , 2010, Nature Reviews Immunology.

[35]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[36]  R. Kontermann,et al.  Cytotoxic T Lymphocytes Responding to Low Dose TRP2 Antigen are Induced Against B16 Melanoma by Liposome-encapsulated TRP2 Peptide and CpG DNA Adjuvant , 2006, Journal of immunotherapy.

[37]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[38]  E. Schmitt,et al.  A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes. , 2014, Angewandte Chemie.

[39]  V. Apostolopoulos,et al.  MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines , 2000, Cancer Immunology, Immunotherapy.

[40]  W. Dippold,et al.  Towards the Development of Antitumor Vaccines: A Synthetic Conjugate of a Tumor-Associated MUC1 Glycopeptide Antigen and a Tetanus Toxin Epitope. , 2001, Angewandte Chemie.

[41]  D. Lasič.  Novel applications of liposomes. , 1998, Trends in biotechnology.

[42]  V. Braun,et al.  Covalent lipoprotein from the outer membrane of Escherichia coli. , 1975, Biochimica et biophysica acta.

[43]  Brendan L Wilkinson,et al.  Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. , 2011, Angewandte Chemie.

[44]  B. Frisch,et al.  Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. , 2004, Bioconjugate chemistry.

[45]  K. A. Wall,et al.  Synthesis of a single-molecule L-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. , 2010, Journal of the American Chemical Society.

[46]  B. Rosner,et al.  Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[47]  M. Oka,et al.  MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. , 2005, Anticancer research.

[48]  P. Wang,et al.  L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies. , 2011, ACS chemical biology.

[49]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[50]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[51]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[52]  A. M. Abdel-Aal,et al.  Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist , 2014, Chembiochem : a European journal of chemical biology.

[53]  E. Schmitt,et al.  Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. , 2008, Angewandte Chemie.

[54]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[55]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[56]  J. Gariépy,et al.  Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. , 2010, Cancer research.

[57]  Marko Vuskovic,et al.  Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. , 2009, Molecular immunology.

[58]  Shixia Wang,et al.  Increased Immunogenicity of Human Immunodeficiency Virus gp120 Engineered To Express Galα1-3Galβ1-4GlcNAc-R Epitopes , 2006, Journal of Virology.

[59]  R. Kerns,et al.  Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. , 2005, Vaccine.

[60]  O. Finn,et al.  Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas , 2013, Annals of the New York Academy of Sciences.

[61]  Kohzoh Imai,et al.  Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer , 2003, International journal of cancer.

[62]  R. Day,et al.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer , 2005, Cancer Immunology, Immunotherapy.

[63]  M. Owais,et al.  Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection. , 2007, Vaccine.

[64]  R. Andino,et al.  Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen , 1999, Nature.

[65]  H. Kunz,et al.  The development of synthetic antitumour vaccines from mucin glycopeptide antigens. , 2013, Chemical Society reviews.

[66]  M. Lotze,et al.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. , 1996, The Journal of surgical research.

[67]  P. V. van Diest,et al.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Irimura,et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.

[69]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[70]  K. Lloyd,et al.  Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. , 1996, Cancer research.

[71]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[72]  Christopher G. Parker,et al.  Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators. , 2013, ACS chemical biology.

[73]  C. Figdor,et al.  Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. , 2013, Blood.

[74]  U. Galili.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. , 1993, Springer seminars in immunopathology.